Please assess the completion status of the following clinical trial:

Trial Title: S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC)~* Evidence of disease by CT scan of the chest~* Measurable or evaluable disease outside of area of prior surgical resection~* No malignant pericardial or pleural effusions (cytologically positive effusions or exudative effusions not attributable to other etiologies)~* No CNS disease by chest CT scan or MRI~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine no greater than upper limit of normal OR~* Creatinine clearance at least 60 mL/min~Other~* No prior hypersensitivity or contraindication to monoclonal antibody 11D10 anti-idiotype vaccine (TriAb), monoclonal antibody GD2 anti-idiotype vaccine (TriGem), or aluminum hydroxide~* No known sensitivity to rodent proteins (i.e., anti-OKT-3, ONCOSCINT scan)~* No grade 1 or greater symptomatic sensory neuropathy~* No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer in complete remission, or any other cancer for which patient has been disease free for 5 years~* If significant clinical hearing loss already present, must accept risk of further hearing loss~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior biologic therapy for SCLC~* No prior TriAb or TriGem~* No prior murine antibodies~* No prior mouse proteins~* At least 30 days since prior immunotherapy~* At least 30 days since any prior immunization~Chemotherapy~* No prior systemic chemotherapy for SCLC~* No concurrent cyclophosphamide or methotrexate~Endocrine therapy~* At least 30 days since prior systemic corticosteroids~* No concurrent systemic corticosteroids (except as an antiemetic)~Radiotherapy~* No prior radiotherapy to the thorax or neck region~* No concurrent intensity modulated radiotherapy~Surgery~* See Disease Characteristics~* At least 2 weeks since prior thoracic or other major surgery and recovered~Other~* At least 30 days since prior investigational agents or devices~* No other concurrent investigational agents~* No other concurrent immunosuppressants (e.g., cyclosporine)~* No concurrent chronic systemic antihistamines~* No concurrent amifostine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cisplatin and etoposide followed by vaccine (Type: EXPERIMENTAL): standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy